Request Demo
Last update 13 Jun 2025
Beijing Gene Key Life Technology Co., Ltd
Private Company | Subsidiary Company|2015|Beijing Shi, China|
10-50
Private Company | Subsidiary Company|2015|Beijing Shi, China|
10-50
Last update 13 Jun 2025
Overview
Tags
Digestive System Disorders
Neoplasms
iNKT cell therapy
CAR-NKT
Natural killer T cell
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20244871
GKL-006注射液用于不可切除的原发性肝细胞癌（HCC）患者的开放、多次给药的安全性、耐受性和PK/PD的Ib期临床试验
[Translation] An open-label, multiple-dose phase Ib clinical trial to evaluate the safety, tolerability, and PK/PD of GKL-006 injection in patients with unresectable primary hepatocellular carcinoma (HCC)
CTR20240402
GKL-006 注射液联合经肝动脉化疗栓塞术（TACE）对比单纯TACE 用于不可切除的肝细胞癌患者中开放、对照单次给药的安全性、耐受性和 PK/PD 的 I 期临床试验
[Translation] Phase I clinical trial of the safety, tolerability and PK/PD of GKL-006 injection combined with transarterial chemoembolization (TACE) versus TACE alone in patients with unresectable hepatocellular carcinoma
NCT05962450
An Open Label, Randomized, Controlled, Clinical Trial of Adoptive Autologous Invariant Natural Killer T Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
100 Clinical Results associated with Beijing Gene Key Life Technology Co., Ltd
Login to view more data
Login to view more data
100 Deals associated with Beijing Gene Key Life Technology Co., Ltd
Login to view more data
100 Translational Medicine associated with Beijing Gene Key Life Technology Co., Ltd
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 08 Jul 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
1
Phase 1
Phase 2
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free